维普中文期刊产品整合服务
18篇 您的检索式:作者名="Turtle CJ"
    题名 作者 年代 出处 被引量
1Dendritic cells in tumor immunology and immunotherapy显示文摘Turtle CJ Hart DN 2004Curr Drug Targets2004,5,:1
2Chimeric antigen receptor modified T cell therapy for B cell malignancies显示文摘Turtle CJ 2014Int J Hematol2014,99,2:1
3Dendritic cells in tumor immunology and immunotherapy显示文摘Turtle CJ Hart DN 2004Curr Drug Targets2004,5,1:1
4Adoptive transfer of virus - specific and tumor - specific T cell immunity 显示文摘Berger C Turtle CJ Jensen MC 2009Curr Opin Im- munol2009,21,2:1
5Immunoselec?tion of functional CMRF-56+ blood dendritic cells from mul?tiple myeloma patients for immunotherapy显示文摘Radford KJ Turtle CJ Kassianos AJ 20051 Immunoth?er2005,28,:1
6Genetically retargeting CD8 lymphocyte subsets for cancer immunotherapy 显示文摘Turtle CJ Riddell SR 2011Curr Opin Immunol2011,23,2:1
7Dendritic cells in tumor immunology and immunotherapy显示文摘Turtle CJ Hart DN 2004Curr Drug Targets2004,5,1:1
8Anti-CD19 chimeric antigen receptor- modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR- T cells and clinical outcomes 显示文摘Turtle CJ Maloney DG 2015Blood ( ASH annual meeting Abstracts )2015,126,21:1
9Normally occurring NKG2D +CD4+ T cells are immunosuppressive and inversely correlatedwith disease activity in juvenile-onset lupus显示文摘Dai Z Turtle CJ Booth GC 2009J Exp Med2009,206,4:1
10Dendritic cells in tumor immunology and immunotherapy显示文摘Turtle CJ Hart DN 2004Curr Drug Targets2004,5,1:1
11Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy显示文摘Turtle CJ Riddell SR 2011Curr Opin Immunol2011,23,2:1
12CD11C+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression显示文摘Radford KJ Turtle CJ Kassianos AJ 0,,:1
13Dendritic cells in tumor immunology and immunotherapy显示文摘Turtle CJ Hart DN 0,,01:1
14Anti-CD 19 chimericantigen receptor-modified T cell therapy for B cell non-Hodgkinlymphoma and chronic lymphocytic leukemia: fludarabine andcyclophosphamide lymphodepletion improves in vivo expansion andpersistence of CAR-T cells and clinical outcomes 显示文摘Turtle CJ Berger C Sommermeyer D 2015Blood ( ASHannual meeting Abstracts )2015,126,21:1
15Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia显示文摘Turtle CJ Hanafi LA Berger C 2015Blood2015,126,:1
16Artificial antigen presenting cells for use in adoptive immunotherapy 显示文摘Turtle CJ Riddell SR 2010Cancer]2010,16,4:1
17Chimeric antigen receptor modified T cell therapy for B cell malignancies 显示文摘Turtle CJ 2014Int J Hematol2014,99,:1
18Dendritic cells in tumor immunology and imunotherapy显示文摘Turtle CJ Hart DN 2004Curr Drug Targets2004,5,:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费